BioCryst Pharma (BCRX) Tops Q2 EPS by 11c, provides product guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $7.78 +0.39%
Revenue Growth %: +3.9%
Financial Fact:
Net loss: -11.53M
Today's EPS Names:
ORPB, PBCO, SICP, More
Revenue Growth %: +3.9%
Financial Fact:
Net loss: -11.53M
Today's EPS Names:
ORPB, PBCO, SICP, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of ($0.06), $0.11 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $109.33 million versus the consensus estimate of $98.3 million.
Guidance:
Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)—
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Customers Bancorp (CUBI) Tops Q3 EPS by 11c
- AppFolio (APPF) Tops Q3 EPS by 3c; Offers Outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
